Abstract. Cluster of differentiation (CD) 109 is a glycosylphosphatidylinositol-anchored cell surface glycoprotein and a co-receptor for transforming growth factor β. The expression of CD109 has been detected in squamous cell carcinoma of the lung, esophagus, skin and gallbladder. The aim of the present study was to evaluate CD109 expression in penile squamous cell carcinoma (PSCC). CD109 expression in PSCC tumor and adjacent tissues from 45 specimens in tissue microarrays was examined by immunohistochemical analyses. In addition, 3 fresh surgical samples of PSCC were collected and examined for their CD109 mRNA and protein levels by reverse transcription-quantitative polymerase chain reaction, western blotting and immunofluorescence staining. CD109 transcription and expression were significantly higher in the PSCC tissues compared with adjacent normal penile tissues, and its expression was restricted to squamous cells. However, CD109 expression level was not associated with the PSCC differentiation grade. These results suggest that CD109 may be associated with the pathogenesis of PSCC, and may therefore be a potential therapeutic target.
Introduction
Penile cancer (PC) significantly affects male physical, mental and sexual health. In Western Europe and the United States, PC accounts for 0.4-0.6% of all cases of malignancy, whereas its incidence is higher in the developing nations of Asia, Africa and South America (1, 2) . Penile squamous cell carcinoma (PSCC), which comprises the majority of cases of PC, arises from the squamous epithelium of the glans, coronal sulcus or inner preputial surface (3) . It is most common in 40-60 year-old patients with a redundant prepuce or phimosis (4) , and is classically graded using the Broders classification system as low-(I-II) or high-grade (III-IV) lesions (5) . PSCC causes significant morbidity and mortality in patients throughout the world. Despite advances in treatment, the prognosis of PSCC remains poor; a large-scale population-based investigation indicated that the survival of the patients with PSCC has not improved during the previous 20 years (6) . When identified, PSCC-specific biomarkers may serve as chemotherapeutic targets. In addition, combinations of the biomarkers may provide diagnostic and prognostic value for clinical treatment. At present, relatively few efficient biomarkers for PSCC have been identified (7) .
Cluster of differentiation (CD) 109, a glycosylphosphatidylinositol-anchored glycoprotein, is one of the members of the α2 macroglobulin/C3, C4, C5 family (8) . Its physiological functions are largely unknown (9) . CD109 binds to transforming growth factor-β1 (TGF-β1) and promotes the internalization of TGF-β receptors (10) (11) (12) . Analyses of CD109 gene expression pattern in human tissues indicated that its transcript is primarily expressed in the testis (13) . Elevated expression of the CD109 gene and/or protein has been detected in lung, esophageal, skin, gallbladder and cervical squamous cell carcinomas (SCCs) (14) (15) (16) (17) (18) . However, CD109 expression in PSCC has yet to be studied.
The aim of the present study was to investigate the expression of CD109 and its association with tumor grade in tumor tissue from patients with PSCC. The expression of CD109 in PSCC was examined by immunohistochemistry, immunofluorescence, western blotting and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in tissue samples and tissue microarrays (TMAs). The results suggested that CD109 expression was significantly increased in PSCC. Therefore, CD109 may be suitable as a novel biomarker or therapeutic target for PSCC. Evaluation of immunohistochemical staining. Subsequent to staining, images of the TMAs were captured with an Olympus FSX100 imaging system (Olympus Corporation, Tokyo, Japan) and analyzed by ImagePro Plus 6.0 software (Media Cybernetics, Inc., Rockville, MD, USA). Integral optical density (IOD) and percentage of expression (PE) were calculated and analyzed.
CD109 expression is upregulated in
RT-qPCR. Total RNA from the fresh PSCC samples and paired adjacent tissues was extracted with the E.Z.N.A. ® Total RNA kit II (cat. no., R6934-02; Omega Bio-Tek, Inc., Norcross, GA, USA) according to the manufacturer's protocol. RT was performed using the RevertAid First Strand cDNA synthesis kit (cat. no., K1622; Thermo Fisher Scientific, Inc.; Waltham, MA, USA). qPCR was performed using SuperRealPreMix Plus with SYBR Green (cat. no., FP205-02; Tiangen Biotech Co., Ltd., Beijing, China) on the ViiA7 DX Real-Time PCR system (Thermo Fisher Scientific, Inc.) as follows: 95˚C for 15 min followed by 40 cycles of 95˚C for 10 sec, 60˚C for 20 sec and 72˚C for 32 sec. The sequences of primers for CD109 and GAPDH are included in Table I . All PCR reactions were repeated in triplicate. CD109 gene expression was assessed by comparing the relative expression level of CD109 with the internal reference GAPDH by the 2 -ΔΔCq method (20) .
Western blot analysis. Patient tissues were homogenized in radioimmunoprecipitation assay buffer (20 mM Tris pH 7.5, 150 mM NaCl, 50 mM NaF, 1% NP40, 0.1% DOC, 0.1% SDS, 1 mM EDTA, 1 mM PMSF, 1 µg/ml leupeptin) and proteins were collected in the supernatant following centrifugation at 10,000 x g at 4˚C for 15 min. Protein concentrations were determined using a bicinchoninic acid assay (Bio Rad Laboratories, Inc., Hercules, CA, USA). An equal amount of protein per lane (30 µg) from each sample was electrophoresed on a 10% SDS-PAGE gel, then transferred to a polyvinylidene fluoride membrane. The membrane was blocked with 2.5% non-fat milk in Tris-buffered saline with Tween-20 (TBST) at 37˚C for 90 min prior to being incubated with the primary antibody overnight at 4˚C. Subsequent to washing with TBST 3 times, the membrane was incubated with the secondary antibody at 37˚C for 1 h. The primary antibodies used were rabbit polyclonal anti-CD109 antibody (dilution, 1:500; cat. no., 18715-1-AP; ProteinTech Group Inc.) and rabbit polyclonal anti-GAPDH (dilution, 1:3,000; cat. no., 10494-1-AP; ProteinTech Group, Inc.; Wuhan Sanying Biotechnology). The secondary antibody was horseradish peroxidase-conjugated anti-rabbit IgG (dilution, 1:6,000; cat. no., SA00001-2; ProteinTech Group, Inc.; Wuhan Sanying Biotechnology). The membranes were visualized with an enhanced chemiluminescence reagent (cat. no., WBKLS0500; Merck KGaA).
Immunofluorescence. The fresh PSCC samples and matching adjust tissues were frozen in optimal cutting temperature compound and cut into 6 µM sections. The sections were fixed with pre-cooled 95% methyl alcohol at room temperature for 5 min, washed 3 times with PBS and stained with a polyclonal rabbit anti-human CD109 antibody (dilution, 1:50; cat. no., HPA009292; Sigma-Aldrich; Merck KGaA) overnight at 4˚C. Subsequent to washing, the sections were incubated with an Alexa546-labeled anti-rabbit secondary antibody (1:200; cat. no., A10040; Thermo Fisher Scientific, Inc.) at room temperature for 1 h. Nuclear staining was performed with DAPI (cat. no., 10236276001; Roche Diagnostics GmbH, Mannheim, Germany) and samples were imaged with a fluorescence microscope at x100 magnification (Olympus Corporation).
Statistical analysis. The student's t-test was used for comparison of two groups. Analysis of variance with post-hoc Tukey's honest significant difference test was used for multiple comparisons. P<0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using SPSS 19.0 statistical software (IBM Corp., Armonk, NY, USA).
Results

CD109 is overexpressed in PSCC tissues from
TMAs. CD109 expression in human PSCC tissues was analyzed by immunohistochemical staining using TMAs with the anti-CD109 antibody, as previously described (17) . In the normal penile tissues, CD109 expression was relatively low and confined primarily to the basal cells of the epidermis (Fig. 1A) . In the well, moderately and poorly differentiated PSCC samples, the sheets or strands of malignant squamous cells exhibited evident brownish CD109 staining in the membrane and cytosol (Fig. 1B-D Fig. 2A and B). It was previously identified that CD109 expression was inversely correlated with tumor grade in cutaneous and esophageal SCCs (16, 17) . However, no statistically significant association of tumor grade with IOD (P=0.27) or PE (P=0.12) was identified between well, moderately and poorly differentiated PSCCs (Table II) .
mRNA and protein levels of CD109 are elevated in fresh surgical samples of PSCC. A total of 3 fresh surgical samples of PSCC were collected, and CD109 expression was examined with RT-qPCR, western blotting and immunofluorescence.
As indicated in Fig. 3A , the mRNA level of CD109 was significantly upregulated in PSCC tumors compared with normal adjacent tissues in all 3 patients (P<0.01, P<0.01 and P<0.05, respectively). Western blotting demonstrated a markedly higher protein level of CD109 in PSCC tissues compared with the CD109 expression in normal adjacent tissues, which was absent or low (Fig. 3B) . The immunofluorescence staining of the fresh tissue sections demonstrated a similar expression pattern as the TMAs; CD109 was highly expressed in the malignant squamous cells of PSCC tissue, whereas there was low CD109 expression in the basal cells of the normal epidermis (Fig. 3C) . Therefore, it was demonstrated that CD109 expression is upregulated in the malignant squamous cells of PSCC tissue.
Discussion
Approximately 95% of cases of PC are of squamous epithelial origin, including in situ and invasive PSCCs (4). Previous studies have identified a number of biomarkers for PSCC, including p53, cyclin D1 and Ki-67 (7). However, none of them are associated with lymph node metastases of PSCC or exhibit prognostic value (7). It is important to identify an appropriate biomarker for the early diagnosis or prognosis of PSCC. CD109 was previously detected in human tumor cell lines, including glioblastoma, squamous cell carcinoma, osteosarcoma and melanoma (13) . In the present study, it was demonstrated that the CD109 protein was highly expressed in the malignant squamous cells of PSCC TMAs. The expression pattern was validated in fresh surgical samples by immunofluorescence, RT-qPCR and western blotting. These results suggest that CD109 may be associated with the pathogenesis of PSCC. CD109 expression has been identified in normal squamous cells of the skin at a low level (17) . In addition, CD109 is highly expressed in SCCs of various origins. For example, high-level expression of CD109 is frequently detected in lung and oral cavity SCC (15,21); Zhang et al (14) identified that CD109 expression was significantly higher in cervical SCC tissue compared with endometrial adenocarcinoma tissue. In our previous studies, we evaluated CD109 expression in a variety of tumor tissues with immunohistochemical methods, and observed a significantly higher expression of CD109 in SCCs of the skin, esophagus and gallbladder, relative to non-cancer tissue (16) (17) (18) . In the present study, it was observed that CD109 is located on the membrane and in the cytosol of the squamous cells of PSCC tumor tissue, which is consistent with the previous data concerning SCCs in other organs. Therefore, CD109 expression may be upregulated in SCCs, irrespective of tissue origin. CD109 expression has been detected in the endothelial cells of tumor-associated vessels (22, 23) . CD109 is expressed in angiogenic vessels of hepatocellular carcinoma, and is associated with the regulation of tumor progression (22) . In addition, CD109 expression was observed in the circulating endothelial cells of patients with blood cancer and glioblastomas (24, 25) . In the present study, CD109 was not detected in the blood vessels of normal penile or PSCC tissue. CD109 expression is also absent in blood vessels of skin, esophagus, lung and gallbladder SCCs at all stages, and their adjacent normal tissues (16) (17) (18) 21) . These data suggest that CD109 is not expressed in the vascular beds of squamous cells, and is not involved in SCC-associated angiogenesis.
The molecular mechanisms underlying the malignant transformation of a premalignant lesion in the penile remain largely unidentified. CD109 is a co-receptor for TGF-β1. In human keratinocytes, CD109 binds to TGF-β1 and forms a heteromeric complex with TGF-β1 signaling receptors in the presence of TGF-β1, resulting in the negative modulation of TGF-β1 signaling (10) (11) (12) . CD109 promotes TGF-β receptor internalization and degradation by the regulation of Mothers against decapentaplegic homolog 7 (SMAD7) and SMAD-specific E3 ubiquitin protein ligase 2 activity in ubiquitin-mediated proteolysis (8, 26) . In addition, CD109 overexpression inhibited TGF-β1-induced transcriptional activation, antiproliferative effects and wound closure (27, 28) . CD109 has also been demonstrated to regulate tumor growth and cell proliferation in oral cavity SCC and breast cancer Table II . Association of cluster of differentiation 109 expression with the tumor differentiation grade in penile squamous cell carcinoma. cells (21, 29) . TGF-β signaling may cause tumor suppressive or tumor promoting effects. The tumor suppressing function is mediated by the SMAD signaling pathway, and the tumor promoting function is mediated by the phosphoinositide 3-kinase/Akt pathway (30) (31) (32) . CD109 may regulate the development of PSCC by the inhibition of TGF-β signaling. In summary, the present study demonstrated that CD109 is highly expressed in PSCC tissues and may be suitable for use as a PSCC biomarker. As a surface protein, it may exhibit potential as a molecular target for PSCC therapy. Additional investigation into the role of CD109 in PSSC may facilitate the early diagnosis and treatment of the disease.
Tumor differentiation ------------------------------------------------------------------------------------------------------------------
